Lupin receives USFDA approval for its generic version of Tolvaptan tablets, indicated for autosomal dominant polycystic ...

A physical therapist was shocked to learn that for her, some of her crucial organs had an expiration date. With proactive ...

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

Pharma major Lupin Ltd on Thursday said it has  received approval from the US health regulator for its generic version of ...

Shawn Kortes, known for his philanthropic work in the community, started dialysis this year and is searching for a kidney ...

Polycystic kidney disease (PKD) is a genetic disorder whereby a large number of cysts develop primarily within the kidneys, but also in other organs. PKD can be autosomal dominant (one mutated ...

Mumbai: Global pharma major, Lupin Limited, has received approval from the United States Food and Drug Administration (U.S.

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic ...

A study of real-world patients with ADPKD supports tolvaptan’s role in slowing annual eGFR decline. Treatment with tolvaptan modestly but significantly attenuates long-term decline of kidney ...

The drug, a copy of Jynarque, could add up to $200 million in annual revenue by FY26, strengthening Lupin’s foothold in ...

The approval includes multiple strengths: 15mg, 30mg, 45mg, 60mg, and 90mg, allowing for flexible dosing options.